Biocon’s profit for the fourth quarter (Q4) of the financial year 2025 has increased by 154% compared to last year, reaching ₹344 crore. The company’s revenue also grew by 12.76% year-on-year, totaling ₹4,417 crore for the quarter.
The company’s profit before tax (PBT) in Q4 FY25 was ₹487 crore, which is a 53% increase from ₹319 crore in the same period last year. Earnings before interest, tax, depreciation, and amortization (EBITDA) grew by 15%, reaching ₹1,115 crore in Q4 FY25, compared to ₹964 crore in Q4 FY24.
Read More: L&T Shares Rise 3.9% as Q4 Profit Jumps 25% Year-on-Year to ₹5,497 Crore
A major driver of this growth was Biocon’s generics business, which grew by 45.81% to ₹718.40 crore in Q4 FY25. This boost was mainly due to the sale of Lenalidomide capsules in the U.S. after a legal settlement with the original manufacturer. The growth was also supported by the launch of Biocon’s first diabetes treatment, Liraglutide, in the UK, which was also approved for chronic weight management.
Biocon Biologics, the part of Biocon that deals with biosimilars (medicines similar to branded ones), saw an 8% increase in revenue, totaling ₹2,463 crore. Syngene, Biocon’s research services division, reported an 11% increase in revenue, reaching ₹1,018 crore.
The company’s research and development (R&D) expenses decreased by 6% to ₹231 crore compared to last year.
Also See: Britannia Industries Q4 Results: Profit Jumps 4% to ₹560 Crore with ₹75 Dividend
Kiran Mazumdar-Shaw, Biocon’s Chairperson, said the company had a strong performance across its businesses and is now entering new markets. They launched Liraglutide in the UK and introduced a new biosimilar product, Yesintek (bUstekinumab), in the U.S. The company also expanded its biologics manufacturing by acquiring a new facility in the U.S.
Biocon’s board of directors has recommended a final dividend of ₹0.50 per share for the year, which is 10% of the face value of the share.
Additionally, Peter Bains has been appointed the CEO and Managing Director of Syngene, and will step down as the Group CEO of Biocon from 1 April 2025. The company also announced plans to raise up to ₹4,500 crore by issuing new securities, and is exploring options to restructure, including the potential merger of Biocon Biologics and Biocon.
Also See: Titan’s Shares Rise 3.2% as Quarterly Profit Grows 13% YoY to ₹871 Crore
Despite the strong results, Biocon’s stock price dropped by 1.55%, closing at ₹329.40 on the BSE.
Biocon is a global biopharmaceutical company known for producing medicines for chronic diseases such as diabetes, cancer, and autoimmune disorders. It has developed and marketed both biologics and generic medicines in India, the U.S., Europe, and other key markets.
